Cuprina Holdings (Cayman) Limited (CUPR)
| Market Cap | 6.10M |
| Revenue (ttm) | 38,791 |
| Net Income (ttm) | -3.63M |
| Shares Out | 21.45M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 519,620 |
| Open | 0.290 |
| Previous Close | 0.292 |
| Day's Range | 0.280 - 0.303 |
| 52-Week Range | 0.280 - 9.500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About CUPR
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste; and products using m... [Read more]
Financial Performance
In 2024, CUPR's revenue was 48,321, a decrease of -52.05% compared to the previous year's 100,773. Losses were -1.56 million, 39.4% more than in 2023.
Financial numbers in SGD Financial StatementsNews
CUPR Investors Have Opportunity to Join Cuprina Holdings (Cayman) Limited Fraud Investigation with the Schall Law Firm
LOS ANGELES, April 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cuprina Holdings...
Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board
SINGAPORE, March 11, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic woun...
Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wound...
Cuprina Signs MOU with Singapore Biowaste Solutions to Integrate Medical Waste Management Technologies
SINGAPORE, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wound...
Cuprina to Present Live, Answer Questions, at Skyline Signature Series™ on October 8th, 2025, at 11:00 AM ET
Individual and institutional investors, advisors, and analysts are invited to attend Individual and institutional investors, advisors, and analysts are invited to attend
Cuprina Secures Exclusive Rights to Southeast Asia's First UNIDO/GEF- Demonstrated Medical Waste Recycling Technology
SINGAPORE, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and com...
Are You Holding These 6 Potential Pump-And-Dump Stocks? The Bear Cave Sees These As The Next Targets
Last week, The Bear Cave investigative financial newsletter warned of widespread pump-and-dump scams coordinated via WhatsApp groups and fake investment firms that target U.S.-listed Chinese stocks.
Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market
SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commerc...
Cuprina Provides Update on Research Studies with Three Leading Education Institutes
SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and comm...
Cuprina Completes Lab Able to Supply MEDIFLY Chronic Wound Therapy Across MENA Region, Secures Exclusive License to Market Medicinal Leeches in GCC Countries
SINGAPORE, June 04, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commerc...
Cuprina Holdings Announces Closing of Underwriter's Over-Allotment Option in Connection with Initial Public Offering
SINGAPORE, May 08, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and comme...
Cuprina Holdings Announces Completion, Receipt of Certification and License, for IVF Media Production Facility Built in Collaboration with Ferti-Craft Pte Ltd.
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and comme...
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commerci...
Cuprina Holdings (Cayman) Limited Announces Pricing of $12 million Initial Public Offering
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of pr...